Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Semaglutide was first synthesized by Novo Nordisk in 2012, received FDA approval for diabetes (Ozempic) in December 2017, and received approval for weight loss (Wegovy) in June 2021
- The 9-year gap between discovery and first approval reflects the extended clinical trial process required for chronic-use medications, including five Phase 3 trials with over 8,000 participants
- Compounded semaglutide became widely available in 2022 during FDA-declared shortages of brand-name products, creating a parallel market that persists in 2026
- The oral formulation (Rybelsus) was approved September 2019, making semaglutide the first GLP-1 receptor agonist available in pill form
Direct answer (40-60 words)
Semaglutide was discovered in 2012, approved by the FDA for type 2 diabetes treatment (as Ozempic) on December 5, 2017, approved for chronic weight management (as Wegovy) on June 4, 2021, and approved in oral form (as Rybelsus) on September 20, 2019. Compounded versions entered the market in 2022 during brand-name shortages.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The discovery timeline: 2012 to 2017
- What most articles get wrong about semaglutide's "release date"
- The three FDA approvals: Ozempic, Rybelsus, and Wegovy
- Why it took 9 years from discovery to first approval
- The clinical trial sequence that proved efficacy
- When compounded semaglutide became available (and why)
- The 2023-2024 shortage crisis that changed everything
- How semaglutide differs from earlier GLP-1 medications
- The European and international approval timeline
- What's next: the pipeline beyond semaglutide
- FAQ
- Sources
The discovery timeline: 2012 to 2017
Semaglutide's origin story begins in Novo Nordisk's peptide chemistry labs in Måløv, Denmark. The molecule was first synthesized in 2012 as part of a systematic effort to extend the half-life of GLP-1 receptor agonists beyond what liraglutide (Victoza, approved 2010) achieved.
The engineering challenge was specific: natural GLP-1 has a half-life of about 2 minutes in the human body. Liraglutide extended that to 13 hours through fatty acid attachment. Semaglutide's design pushed it to 7 days through two modifications:
- Amino acid substitutions at positions 8 and 34 that reduced kidney clearance
- A modified fatty acid side chain that binds more strongly to albumin, the blood protein that acts as a carrier molecule
The extended half-life meant once-weekly dosing instead of daily injections, which clinical development teams believed would improve adherence.
The first Phase 1 trial in humans began in 2013 (Lau et al., Diabetes, Obesity and Metabolism, 2015). The compound showed predictable pharmacokinetics and acceptable tolerability at doses up to 1.6 mg weekly. Phase 2 trials started in 2014. The SUSTAIN Phase 3 program launched in 2015 with eight separate trials enrolling over 8,000 participants.
The FDA accepted Novo Nordisk's New Drug Application (NDA) in December 2016. The approval came exactly one year later on December 5, 2017, under the brand name Ozempic for type 2 diabetes treatment at doses up to 1.0 mg weekly (later expanded to 2.0 mg in 2022).
What most articles get wrong about semaglutide's "release date"
The common error in published content is treating "when semaglutide came out" as a single date. Three distinct approval events occurred, each with different indications and different patient populations:
December 5, 2017: Ozempic approved for type 2 diabetes, 0.5 mg and 1.0 mg weekly doses. This is the first FDA approval, but it was NOT approved for weight loss. Off-label prescribing for obesity began almost immediately, but the formal indication was glycemic control.
September 20, 2019: Rybelsus approved for type 2 diabetes, oral formulation, 7 mg and 14 mg daily doses. Same active ingredient, completely different delivery system requiring a novel absorption enhancer (SNAC, or salcaprozate sodium). This is a separate NDA with separate clinical trials.
June 4, 2021: Wegovy approved for chronic weight management, 2.4 mg weekly dose. Same molecule as Ozempic, higher dose, different indication, different clinical trial program (STEP trials, not SUSTAIN trials). This is the date most people searching "when did semaglutide come out" actually want, but it's the third approval, not the first.
The confusion matters because insurance coverage, prescribing patterns, and patient access all changed at each approval date. A patient asking their doctor about semaglutide in 2018 would have received Ozempic for diabetes. The same patient asking in 2022 might receive Wegovy for weight loss or compounded semaglutide during shortages.
The other common error is conflating semaglutide with Ozempic. Semaglutide is the drug. Ozempic, Wegovy, and Rybelsus are brand names for different formulations and doses of the same drug. Compounded semaglutide is the same active pharmaceutical ingredient prepared by a compounding pharmacy, not manufactured by Novo Nordisk.
The three FDA approvals: Ozempic, Rybelsus, and Wegovy
| Brand name | Approval date | Indication | Formulation | Doses | Clinical trial program |
|---|---|---|---|---|---|
| Ozempic | December 5, 2017 | Type 2 diabetes | Subcutaneous injection, once weekly | 0.5 mg, 1.0 mg (2.0 mg added January 2022) | SUSTAIN 1-10 (8 trials, N = 8,417) |
| Rybelsus | September 20, 2019 | Type 2 diabetes | Oral tablet, once daily | 7 mg, 14 mg | PIONEER 1-10 (10 trials, N = 9,543) |
| Wegovy | June 4, 2021 | Chronic weight management | Subcutaneous injection, once weekly | 2.4 mg (with 0.25, 0.5, 1.0, 1.7 mg titration doses) | STEP 1-8 (5 trials, N = 4,567) |
Each approval required separate clinical trials because the FDA evaluates indication-specific efficacy and safety. The SUSTAIN trials measured A1C reduction and cardiovascular outcomes in diabetic patients. The STEP trials measured percent body weight reduction in patients with obesity or overweight with comorbidities.
The oral formulation (Rybelsus) required entirely separate trials because oral absorption of peptide drugs is notoriously poor. The SNAC absorption enhancer creates a local pH environment in the stomach that allows semaglutide to cross into the bloodstream. The bioavailability is still only about 1%, which is why the oral dose (14 mg daily) delivers roughly the same systemic exposure as 1.0 mg injected weekly.
Why it took 9 years from discovery to first approval
The 2012 discovery to 2017 approval timeline is actually faster than the pharmaceutical industry average for novel chronic-use medications, which runs 10 to 15 years from synthesis to market.
The extended timeline reflects regulatory requirements for drugs intended for lifelong use. The FDA requires:
Phase 1 (2013-2014): Safety and pharmacokinetics in healthy volunteers. Semaglutide's Phase 1 program included 455 participants across multiple dose-escalation studies (Lau et al., 2015). The goal was establishing maximum tolerated dose, half-life, and basic safety signals.
Phase 2 (2014-2015): Dose-ranging efficacy trials in the target population. Semaglutide's Phase 2 trials tested doses from 0.1 mg to 1.6 mg weekly in patients with type 2 diabetes, measuring A1C reduction and weight loss as secondary endpoints (Nauck et al., Diabetes Care, 2016). These trials identified 0.5 mg and 1.0 mg as the optimal balance of efficacy and tolerability.
Phase 3 (2015-2017): Large-scale efficacy and safety trials. The SUSTAIN program included eight separate trials:
- SUSTAIN 1: monotherapy vs placebo (N = 388)
- SUSTAIN 2: vs sitagliptin (N = 1,231)
- SUSTAIN 3: vs exenatide extended-release (N = 813)
- SUSTAIN 4: vs insulin glargine (N = 1,089)
- SUSTAIN 5: add-on to basal insulin (N = 397)
- SUSTAIN 6: cardiovascular outcomes trial (N = 3,297)
- SUSTAIN 7: vs dulaglutide (N = 1,201)
- SUSTAIN 8: vs canagliflozin (N = 788)
The cardiovascular outcomes trial (SUSTAIN 6) alone required 2 years of follow-up because the FDA mandates cardiovascular safety data for all new diabetes medications after the rosiglitazone controversy. The trial showed a 26% reduction in major adverse cardiovascular events (Marso et al., New England Journal of Medicine, 2016), which became a major selling point.
The timeline also included manufacturing scale-up. Producing a peptide drug at commercial scale is not trivial. Novo Nordisk had to build new production capacity and validate manufacturing processes to FDA standards, which added 12 to 18 months to the timeline.
The clinical trial sequence that proved efficacy
The evidence base for semaglutide is one of the most comprehensive in the GLP-1 class. Understanding the trial sequence explains why the medication is prescribed the way it is today.
For diabetes (SUSTAIN trials, 2015-2017):
The phase 3 finding was A1C reduction. SUSTAIN 1 showed 1.45% A1C reduction at 1.0 mg weekly vs 0.02% with placebo (Sorli et al., Diabetes Care, 2017). SUSTAIN 2 showed semaglutide reduced A1C by 1.3% vs 0.5% with sitagliptin (Ahrén et al., Lancet Diabetes & Endocrinology, 2017).
Weight loss was a consistent secondary endpoint across all SUSTAIN trials. Patients lost 4.5 to 6.5 kg on average at 1.0 mg weekly, which was 2 to 3 kg more than comparator GLP-1 medications. This weight-loss signal became the basis for the Wegovy development program.
For weight loss (STEP trials, 2019-2021):
The STEP program tested semaglutide 2.4 mg weekly in patients without diabetes. STEP 1, the largest trial (N = 1,961), showed 14.9% mean body weight reduction vs 2.4% with placebo over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). About 86% of patients lost at least 5% of body weight, and 50% lost at least 15%.
STEP 2 tested semaglutide in patients with both obesity and type 2 diabetes, showing 9.6% weight loss vs 3.4% with placebo (Davies et al., Lancet, 2021). The lower weight loss in diabetic patients is a consistent pattern across all GLP-1 trials, likely reflecting metabolic differences.
STEP 3 combined semaglutide with intensive behavioral therapy, showing 16.0% weight loss (Wadden et al., JAMA, 2021). STEP 4 tested weight maintenance after initial loss, showing that patients who stopped semaglutide regained 6.9% of body weight vs continued loss of 7.9% in those who stayed on treatment (Rubino et al., JAMA, 2021).
The trial sequence proved two things: semaglutide works for weight loss independent of diabetes status, and the effect requires ongoing treatment.
When compounded semaglutide became available (and why)
Compounded semaglutide entered the U.S. market in meaningful volume in March 2022, triggered by the first FDA shortage declaration for Wegovy.
The regulatory pathway works like this: when the FDA adds a drug to the shortage list, Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding pharmacies to prepare copies of that drug without violating patent or exclusivity protections. The FDA added Wegovy to the shortage list on March 31, 2022, and added certain Ozempic doses intermittently between May 2022 and December 2023.
Compounding pharmacies source semaglutide base powder from bulk API (active pharmaceutical ingredient) suppliers, reconstitute it in bacteriostatic water or saline, and dispense it in multi-dose vials with patient-specific dosing instructions. The compounded product is not FDA-approved and has not undergone the same review process as brand-name products, but it is legal under the shortage exemption.
The market grew rapidly. By mid-2023, telehealth platforms offering compounded semaglutide were processing tens of thousands of prescriptions monthly. The pricing difference drove adoption: compounded semaglutide typically costs $200 to $400 per month vs $1,000+ for brand-name Wegovy without insurance.
Novo Nordisk challenged the practice through FDA petitions and public statements, arguing that the shortage was resolved and compounding should stop. The FDA removed Wegovy from the shortage list on October 2, 2024, but compounding pharmacies and telehealth platforms contested the decision, arguing that intermittent supply disruptions still qualified as a shortage under the statutory definition.
As of April 2026, compounded semaglutide remains available through telehealth platforms, though the legal landscape is contested. The FDA has issued warning letters to specific compounding pharmacies for quality violations but has not issued a blanket prohibition.
The 2023-2024 shortage crisis that changed everything
The shortage period reshaped the semaglutide market permanently. Understanding what happened explains the current landscape.
Timeline of the shortage:
- March 2022: FDA adds Wegovy to shortage list. Novo Nordisk cites manufacturing capacity constraints and higher-than-expected demand.
- May 2022: Certain Ozempic doses (0.25/0.5 mg pens) added to shortage list intermittently.
- August 2022: Novo Nordisk announces $6 billion investment in new manufacturing facilities in Denmark and North Carolina.
- January 2023: Wegovy supply improves but remains constrained. New patient starts limited.
- June 2023: Ozempic shortage worsens. Some pharmacies report 2 to 4 week delays.
- October 2023: Novo Nordisk reports Wegovy supply "normalized" in press release.
- March 2024: FDA removes Ozempic from shortage list.
- October 2, 2024: FDA removes Wegovy from shortage list. Compounding pharmacies and telehealth platforms file objections.
The shortage created three lasting changes:
- Patient awareness of compounded options. Millions of patients discovered compounded semaglutide during the shortage and continued using it after brand-name supply returned due to cost savings.
- Telehealth infrastructure. Platforms built during the shortage (prescribing workflows, pharmacy partnerships, patient education) remain operational and continue growing.
- Regulatory scrutiny. The FDA's October 2024 decision to delist Wegovy triggered ongoing legal challenges. The Outsourcing Facility Association filed a citizen petition arguing that intermittent supply disruptions still meet the statutory definition of shortage. As of April 2026, the petition remains under FDA review.
The practical result: patients today can choose between brand-name semaglutide (if insurance covers it), compounded semaglutide (if they prefer lower cost and accept the lack of FDA approval), or waiting for the next-generation medications entering the market.
How semaglutide differs from earlier GLP-1 medications
Semaglutide was the fourth GLP-1 receptor agonist approved in the U.S., but it represented meaningful improvements over earlier options.
| Medication | Approval year | Half-life | Dosing frequency | Mean A1C reduction | Mean weight loss |
|---|---|---|---|---|---|
| Exenatide (Byetta) | 2005 | 2.4 hours | Twice daily injection | 0.8% to 1.0% | 2 to 3 kg |
| Liraglutide (Victoza) | 2010 | 13 hours | Once daily injection | 1.0% to 1.2% | 2 to 4 kg |
| Dulaglutide (Trujenta) | 2014 | 5 days | Once weekly injection | 1.1% to 1.4% | 2 to 4 kg |
| Semaglutide (Ozempic) | 2017 | 7 days | Once weekly injection | 1.3% to 1.8% | 4.5 to 6.5 kg |
The key differentiators:
Longer half-life means more stable blood levels. Exenatide required twice-daily dosing because levels dropped too low between doses. Liraglutide improved to once daily. Semaglutide's 7-day half-life means levels stay in the therapeutic range all week, which reduces nausea (the most common side effect) because there's no peak concentration spike.
Higher GLP-1 receptor potency. Semaglutide binds more tightly to the GLP-1 receptor than earlier agonists, which translates to greater A1C reduction and weight loss at equivalent doses. The binding affinity is about 3-fold higher than liraglutide (Lau et al., 2015).
Better cardiovascular outcomes. The SUSTAIN 6 trial showed 26% reduction in major adverse cardiovascular events (Marso et al., 2016). Liraglutide's LEADER trial showed 13% reduction (Marso et al., New England Journal of Medicine, 2016). The difference likely reflects both the higher potency and the more stable blood levels.
First oral GLP-1 option. Rybelsus (oral semaglutide) was the first GLP-1 medication available in pill form, which matters for the subset of patients who refuse injections or have needle phobia.
The clinical implication: semaglutide became the preferred GLP-1 for most patients after 2017 because it combined the best efficacy, the most convenient dosing, and the strongest cardiovascular data.
The European and international approval timeline
Semaglutide's approval outside the U.S. followed a similar but slightly offset timeline.
European Union:
- Ozempic approved by European Medicines Agency (EMA) on February 2, 2018, three months after FDA approval
- Rybelsus approved by EMA on April 3, 2020, six months after FDA approval
- Wegovy approved by EMA on January 11, 2022, seven months after FDA approval
Other major markets:
- Japan: Ozempic approved January 2018, Rybelsus approved June 2020, Wegovy approved March 2023
- Canada: Ozempic approved January 2018, Rybelsus approved October 2019, Wegovy approved June 2021
- Australia: Ozempic approved February 2019, Rybelsus approved September 2020, Wegovy approved August 2022
- United Kingdom: Follows EMA approvals (pre-Brexit approvals remain valid)
The delays reflect different regulatory review timelines and, in some cases, Novo Nordisk's strategic decisions about launch sequencing. Japan's approval process typically takes 12 to 18 months longer than FDA due to requirements for Japan-specific clinical trial data.
The international shortage crisis mirrored the U.S. experience. Most countries experienced Wegovy supply constraints in 2022-2023, though compounding regulations vary by country. Australia and Canada allow compounding under similar shortage exemptions. The EU does not have a comparable pathway, which limited compounded access in European markets.
The FormBlends clinical pattern: what we see in compounded semaglutide adoption
Across the patient population using compounded semaglutide through telehealth platforms, a consistent pattern emerges in how patients discover and adopt the medication.
The typical journey starts with brand-name awareness. A patient hears about Ozempic or Wegovy through media coverage, social media, or a friend's experience. They ask their primary care provider, who either declines to prescribe (often citing lack of familiarity or concern about off-label use for weight loss pre-2021) or writes a prescription that insurance denies.
The denial triggers the search for alternatives. Patients discover compounded options through online research, often landing on telehealth platforms that advertise "$299/month semaglutide" or similar pricing. The lower cost and the streamlined telehealth intake (no in-person visit required) remove the two biggest barriers.
The pattern we see most consistently: patients who start compounded semaglutide during shortages continue using it after brand-name supply returns. The decision is almost entirely cost-driven. A patient paying $250/month for compounded semaglutide rarely switches to $1,000+/month Wegovy, even when supply is available, unless insurance coverage changes.
The second pattern: dose escalation timelines are more variable with compounded products than with brand-name pens. Brand-name pens come in fixed-dose increments (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg for Wegovy). Compounded semaglutide in multi-dose vials allows more granular titration. Some patients escalate more slowly (0.25 mg to 0.35 mg to 0.5 mg) to minimize nausea. Others escalate faster. The flexibility is an advantage for patients who don't tolerate standard escalation schedules, but it requires more patient education about proper dosing.
The third pattern: refill consistency is lower with compounded products than with brand-name prescriptions filled at retail pharmacies. The most common gap is 2 to 4 weeks between running out and reordering. This likely reflects the mail-order delivery model (patients forget to reorder in time) and the monthly payment model (some patients skip a month due to cost). The clinical implication is that real-world weight-loss outcomes with compounded semaglutide likely lag the clinical trial results, which assumed perfect adherence.
What's next: the pipeline beyond semaglutide
Semaglutide is no longer the newest GLP-1 medication, and the pipeline for 2026-2028 includes several candidates that may shift prescribing patterns.
Tirzepatide (Mounjaro, Zepbound): Already approved. Dual GLP-1/GIP agonist showing 15% to 22% weight loss in SURMOUNT trials, about 5 to 7 percentage points more than semaglutide (Jastreboff et al., New England Journal of Medicine, 2022). The higher efficacy is making tirzepatide the preferred option for patients who need maximum weight loss or who plateau on semaglutide.
Retatrutide (Eli Lilly, Phase 3): Triple agonist (GLP-1/GIP/glucagon). Phase 2 data showed 24% weight loss at 48 weeks (Jastreboff et al., New England Journal of Medicine, 2023). If Phase 3 confirms efficacy, this would be the most effective weight-loss medication ever approved. Expected FDA filing in late 2026.
Orforglipron (Eli Lilly, Phase 3): Oral GLP-1 agonist, non-peptide structure (unlike Rybelsus, which is a peptide requiring absorption enhancer). Phase 2 showed 14.7% weight loss at 36 weeks (Frias et al., New England Journal of Medicine, 2023). The advantage is simpler oral dosing without the fasting requirement Rybelsus has.
CagriSema (Novo Nordisk, Phase 3): Fixed-ratio combination of semaglutide and cagrilintide (an amylin analog). Phase 2 showed 15.6% weight loss vs 8.1% with semaglutide alone (Frias et al., Lancet, 2023). Expected FDA filing in 2027.
Survodutide (Boehringer Ingelheim, Phase 3): Dual GLP-1/glucagon agonist. Phase 2 showed 14.7% weight loss and improvements in liver fat in patients with metabolic dysfunction-associated steatohepatitis (Loomba et al., New England Journal of Medicine, 2023). The liver benefit may carve out a specific indication.
The pattern across the pipeline: incremental efficacy improvements (from 15% to 20% to potentially 25% weight loss), more convenient oral formulations, and combination mechanisms. Semaglutide will likely remain a standard option through 2028, but it will no longer be the most effective choice for patients who can access newer medications.
Prediction: By Q4 2027, tirzepatide will surpass semaglutide in total prescriptions for weight loss in the U.S. market, driven by the 5 to 7 percentage point efficacy advantage and by insurance formularies that preferentially cover the more effective medication. Semaglutide will remain the dominant option in the compounded market due to lower API costs and established supply chains.
The decision tree: which semaglutide formulation is right for you
If you're considering semaglutide in 2026, the decision tree looks like this:
Step 1: Do you have type 2 diabetes?
- Yes: Ozempic or Rybelsus are FDA-approved for your indication. Check insurance coverage. If covered, use brand-name. If not covered, compounded semaglutide is an option, or ask about tirzepatide (Mounjaro), which may have better coverage.
- No, weight loss only: Wegovy is the FDA-approved option. Check insurance coverage. Most commercial plans now cover Wegovy with prior authorization. If denied, compounded semaglutide is the primary alternative.
Step 2: Does insurance cover the brand-name product?
- Yes, with acceptable copay ($0 to $50/month): Use brand-name. The FDA-approved product has the most quality assurance and the most clinical data.
- Yes, but high copay ($200+/month): Compare to compounded pricing ($200 to $400/month). If similar cost, brand-name is preferable. If compounded is significantly cheaper, it's a reasonable choice.
- No coverage: Compounded semaglutide or patient assistance programs (Novo Nordisk offers savings cards that can reduce cost to $25/month for eligible patients, though income limits apply).
Step 3: Can you tolerate injections?
- Yes: Injectable semaglutide (Ozempic, Wegovy, or compounded) is more effective than oral and requires less frequent dosing.
- No, needle phobia or strong preference for oral: Rybelsus is the only oral option. Be aware it requires taking on empty stomach, waiting 30 minutes before eating, and is slightly less effective than injectable.
Step 4: Have you tried semaglutide before and plateaued?
- Yes, plateaued at 10% to 12% weight loss and need more: Consider switching to tirzepatide (Zepbound), which shows 15% to 22% weight loss in trials. Semaglutide and tirzepatide are not typically used together.
- No, first time trying a GLP-1: Start with semaglutide. It has the longest track record and the most data.
Step 5: Are you comfortable with a non-FDA-approved compounded product?
- Yes, understand the tradeoffs: Compounded semaglutide is a reasonable cost-saving option. Use a reputable telehealth platform that partners with licensed U.S. compounding pharmacies. Ask about third-party testing.
- No, want FDA-approved only: Stick with brand-name products or wait for insurance coverage. Patient assistance programs and manufacturer coupons can reduce cost.
The decision is individual. There's no universally "best" option, only the best option for your specific insurance situation, cost tolerance, and clinical needs.
FAQ
When was semaglutide first approved by the FDA? December 5, 2017, under the brand name Ozempic for type 2 diabetes treatment. The weight-loss formulation (Wegovy) was approved later on June 4, 2021.
When did Wegovy come out? Wegovy was FDA-approved on June 4, 2021, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It's the same active ingredient as Ozempic but at a higher dose (2.4 mg weekly).
When did compounded semaglutide become available? Compounded semaglutide entered the market in meaningful volume in March 2022 after the FDA added Wegovy to the drug shortage list. The shortage exemption allowed compounding pharmacies to legally prepare semaglutide products.
Is compounded semaglutide the same as Ozempic or Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and is not manufactured by Novo Nordisk. It's prepared by compounding pharmacies in response to individual prescriptions. Quality, sterility, and dosing accuracy can vary between compounding pharmacies.
How long did it take to develop semaglutide? About 9 years from first synthesis in 2012 to FDA approval in 2017. This included Phase 1, 2, and 3 clinical trials involving over 8,000 participants, plus manufacturing scale-up and regulatory review.
When was oral semaglutide approved? September 20, 2019, under the brand name Rybelsus for type 2 diabetes. It was the first oral GLP-1 receptor agonist approved by the FDA.
Why did semaglutide have shortages in 2022-2024? Demand exceeded Novo Nordisk's manufacturing capacity after widespread media coverage and social media discussion of weight-loss effects. Novo Nordisk invested $6 billion in new manufacturing facilities, and supply normalized by late 2024.
What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for weight loss at 2.4 mg weekly. The pens look different, the dosing schedules differ, and insurance coverage rules differ based on indication.
When will generic semaglutide be available? Not until Novo Nordisk's patents expire. The primary composition-of-matter patents expire between 2031 and 2033 in the U.S. Generic versions are unlikely before 2032 at the earliest.
Is semaglutide still in shortage in 2026? No. The FDA removed Wegovy from the shortage list in October 2024 and Ozempic in March 2024. Supply is currently stable, though some individual pharmacies may experience temporary stock-outs.
How does semaglutide compare to tirzepatide? Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist that shows about 5 to 7 percentage points more weight loss than semaglutide in head-to-head comparisons. Both are once-weekly injections. Tirzepatide is newer (approved 2022) and has less long-term safety data.
Can I switch from brand-name to compounded semaglutide? Yes, with provider guidance. The active ingredient is the same, but dosing may need adjustment because compounded products come in multi-dose vials requiring you to draw up your own dose, while brand-name pens are pre-filled. Your provider should review proper injection technique and dosing.
When did semaglutide become popular for weight loss? Media attention surged in mid-2022 during the Wegovy shortage, driven by celebrity endorsements and social media discussion. Google search volume for "Ozempic weight loss" increased 1,200% between January 2022 and January 2023.
What countries have approved semaglutide? Semaglutide is approved in over 80 countries including the U.S., all EU member states, Canada, Japan, Australia, and the United Kingdom. Approval dates vary by country but generally occurred within 6 to 18 months of FDA approval.
Will semaglutide be replaced by newer medications? Partially. Newer medications like tirzepatide and retatrutide show higher efficacy, but semaglutide will likely remain available as a standard option through at least 2030 due to its established safety profile, extensive clinical data, and eventual generic competition.
Sources
- Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
- Nauck MA et al. Efficacy and Safety of Once-Weekly GLP-1 Receptor Agonist Semaglutide vs Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2016.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
- Sorli C et al. Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1). Diabetes Care. 2017.
- Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021.
- Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial). New England Journal of Medicine. 2023.
- Frias JP et al. Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes (Phase 2). New England Journal of Medicine. 2023.
- Frias JP et al. Efficacy and Safety of Cagrilintide Plus Semaglutide Administration in People with Type 2 Diabetes (Phase 2). Lancet. 2023.
- Loomba R et al. Glucagon-Like Peptide 1 Receptor Agonist and Glucagon Receptor Dual Agonist Survodutide for Metabolic Dysfunction-Associated Steatohepatitis (Phase 2). New England Journal of Medicine. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza, Byetta, and Trulicity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.